6-(2-tert-butoxycarbonylhydrazinyl)pyridine-3-carboxamide | 1415887-89-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2-tert-butoxycarbonylhydrazinyl)pyridine-3-carboxamide
• 英文别名: tert-butyl N-[(5-carbamoylpyridin-2-yl)amino]carbamate
• CAS: 1415887-89-6
• 化学式: C₁₁H₁₆N₄O₃
• 分子量: 252.273
• InChiKey: DGJWVOGIPWGKIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS<br/>[FR] SYNTHÈSE EN PHASE SOLIDE DE CONJUGUÉS DÉRIVÉS DE GLUTAMATE-URÉE-LYSINE (DÉRIVÉS DE GUL) CIBLANT L'ANTIGÈNE MEMBRANAIRE PROSTATIQUE SPÉCIFIQUE (AMPS) ET LEUR UTILISATION COMME PRÉCURSEURS D'AGENTS THÉRAPEUTIQUES ET/OU DIAGNOSTIQUES
  申请人：[en]TELIX INTERNATIONAL PTY LTD

  公开号：WO2022178592A1

  公开（公告）日：2022-09-01

  The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process and methods for their preparation such as a method of preparing a compound of formula (V). Also disclosed are use of the conjugates as precursors for therapeutic and / or diagnostic agents, including treating and diagnosing prostate cancer.